Nonetheless, cyclin-dependent kinase 4 and 6 enzyme inhibitors (CDK4/6 inhibitors) are a relatively new class of medications that were approved in first-line treatment alongside endocrine therapy for HR+/HER-2 negative stage IV breast cancer patients after proving their clinical superiority compared to endocrine monotherapy [5]. The gene discussed is CDK4; the disease is breast cancer.